/stocks — the workspaceLOADING
Neumora Therapeutics, Inc. (NMRA) is a biological products, (no diagnostic substances) company. 5 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-05 from NMRA's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
A plain-English read on NMRA plus an auto-SWOT — built from NMRA's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate NMRA using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Milligan Michael LeeSee Remarks | SELL | $5K | view → |
| BERNS PAUL LSee Remarks | SELL | $34K | view → |
| Pinto JoshuaPresident | SELL | $21K | view → |
| Aurora Daljit SinghSee Remarks | SELL | $22K | view → |
Projected from NMRA's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment NMRA files its announcement.
NMRA has sold off after 7 of its last 8 earnings reports.
Large earnings reactions have been common.
NMRA has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+2.5% and -21.5%).
A more typical earnings reaction has been approximately ±6.1%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-07 | -21.5% |
| 2026-03-30 | -16.3% |
| 2025-11-06 | -2.3% |
| 2025-08-06 | -0.6% |
| 2025-05-12 | +2.5% |
| 2025-03-03 | -9.6% |
| 2024-11-12 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -21.0% |
| 2024-08-06 | -1.4% |